Psyence looks to expand capital market opportunities in the UK and Europe

2022-01-21T16:03:46+00:00January 21, 2022|Press Releases|

TORONTO, DATE, 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it is investigating capital market opportunities to access a broader pool of United Kingdom (“UK”) and European investors. This includes a potential dual listing in the UK.